Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis

Open access
Haringman, Jasper J., Gerlag, Danielle M., Smeets, Tom J. M., Baeten, Dominique, van den Bosch, Filip, Bresnihan, Barry, Breedveld, Ferdinand C., Dinant, Huib J., Legay, Francois, Gram, Hermann, Loetscher, Pius, Schmouder, Robert, Woodworth, Thasia, Tak, Paul P.·2006·Arthritis & Rheumatism

Abstract

Objective: Chemokines such as CCL2/monocyte chemotactic protein 1 (MCP‐1) play a key role in leukocyte migration and are potential targets in the treatment of chronic inflammatory disorders. The objective of this study was to evaluate the effects of human anti–CCL2/MCP‐1 monoclonal antibody (ABN912) treatment in patients with rheumatoid arthritis (RA). Methods: Patients with active RA were enrolled in a randomized, placebo‐controlled, dose‐escalation study of ABN912. Infusions were administered on day 1 and day 15. In the dose‐escalation phase, 4 cohorts of 8 patients each underwent serial arthroscopic biopsy of synovial tissue. Immunohistochemistry and digital image analysis were used to characterize biomarkers in synovial tissue. Laboratory evaluation included pharmacokinetic analysis and immunotypic studies of peripheral blood mononuclear cells. To assess the clinical effects of treatment with ABN912, an additional 21 patients were treated with the highest dose tolerated. Results: The total study population comprised 45 patients: 33 patients received ABN912, and 12 patients received placebo. ABN912 treatment was well tolerated. Unexpectedly, there was a dose‐related increase in ABN912‐complexed total CCL2/MCP‐1 levels in peripheral blood, up to 2,000‐fold. There was no detectable clinical benefit of ABN912 compared with placebo, nor did treatment with the study drug result in a significant change in the levels of biomarkers in synovial tissue and peripheral blood. Conclusion: ABN912 treatment did not result in clinical or immunohistologic improvement and may have been associated with worsening of RA in patients treated with the highest dose. The results might be related to the greatly increased level of total CCL2/MCP‐1 in serum that was observed following treatment with ABN912. This observation may be relevant for a variety of antibody‐based therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.21975

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 258

Metadata

Authors
Haringman, J. J., Gerlag, D. M., Smeets, T. J. M., Baeten, D., van den Bosch, F., Bresnihan, B., Breedveld, F. C., Dinant, H. J., Legay, F., Gram, H., Loetscher, P., Schmouder, R., Woodworth, T., & Tak, P. P.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2006-07-25
Volume
54
Issue
8
Pages
2387-2392
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2002584410
Cited by
258
References
16
FWCI
9.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.21975
The paper
Haringman, J. J., Gerlag, D. M., Smeets, T. J. M., Baeten, D., van den Bosch, F., Bresnihan, B., Breedveld, F. C., Dinant, H. J., Legay, F., Gram, H., Loetscher, P., Schmouder, R., Woodworth, T., & Tak, P. P. (2006). A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.21975

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.